[一季报]健康元(600380):健康元药业集团股份有限公司2023年第一季度报告（英文版）
|
时间：2023年04月24日 18:52:54 中财网 |
|
原标题:健康元:健康元药业集团股份有限公司2023年第一季度报告（英文版）
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2023 First Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there are no false representations, misleading statements or material omissions contained in this announcement and accept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this quarterly report, and that there are no false representations, misleading statements or material omissions contained herein, and severally and jointly accept legal responsibility. ? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the first quarterly financial statements have been audited. □Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
| Item | The Reporting Period
(From January to March) | YoY change (%) | | Revenues | 4,559,049,786.82 | -2.11 | | Net profit attributable to shareholders
of the listed company | 462,746,183.03 | 0.48 | | Net profit attributable to shareholders
of the listed company after deduction
of extraordinary gains and losses | 446,772,473.94 | -2.28 | | Net cash flow from operating activities | 248,084,750.71 | -71.55 | | Basic earnings per share (RMB/share) | 0.2404 | -0.31 | | Diluted earnings per share
(RMB/share) | 0.2398 | -0.48 | | Weighted average return on net assets
(%) | 3.49 | Decreased by 0.35 percentage points |
| | As at the end of the
Reporting Period | As at the end of the
previous year | Change as at the
end of the
Reporting Period
as compared to
the end of the
previous year(%) | | Total assets | 36,193,051,015.06 | 35,729,253,651.41 | 1.30 | | Owner's equity attributable to
shareholders of the listed company | 13,365,070,332.08 | 13,121,820,410.55 | 1.85 |
Notes: From January to March 2023, the Company realized revenues of RMB4,559 million, representing a YoY
decrease of 2.11%. Chemical pharmaceuticals realized revenues of RMB2,250 million, representing a YoY
decrease of 16.09%, among which, RMB509 million were from respiratory formulation products, representing
a YoY increase of 41.18%; RMB793 million were from gastroenterology products, representing a YoY decrease of 25.23%; RMB577 million were from gonadotropic hormones, representing a YoY decrease of 21.60%; RMB199 million were from anti-infection products, representing a YoY decrease of 43.29%;and
RMB122 million were from psychiatry products, representing a YoY decrease of 8.25%. APIs and intermediates products realized revenues of RMB1,454 million, representing a YoY increase of 3.44%.
Traditional Chinese Medicine products realized revenues of RMB567 million, representing a YoY increase of
100.68%. Biological products realized revenues of RMB62 million, representing a YoY increase of 12.22%.
Diagnostic reagents and equipment products realized revenues of RMB147 million from, representing a YoY
decrease of 9.54%. Health care products realized revenues of RMB40 million, representing a YoY increase of
46.99%.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
| Item | For the
Reporting Period | Explanation | | Government grants recognized in profit or loss for the current
period (excluding government grants closely related to the
ordinary operating business of the Company and are entitled in
fixed amount or quantity continuously according to the
applicable national polices and standards) | 51,488,223.81 | Government grants through
the profits and losses for the
Period | | Gains and losses on fair value changes incurred from financial
assets held for trading, derivative financial assets, financial
liabilities held for trading and derivative financial liabilities, and
investment income on disposal of financial assets held for
trading, derivative financial assets, financial liabilities held for
trading, derivative financial liabilities and other debt
investments, except for effective hedging activities related to the
ordinary operating business of the Company | -18,242,051.06 | Gains or losses arising from
changes in fair value of
financial assets/liabilities
held for trading, and
investment gains from
holding and disposal of
financial assets/liabilities
held for trading | | Other non-operating income and expenses excluding the above
items | -2,822,249.38 | Other non-operating income
and expenses excluding the
above items | | Less: Effect of income tax | 7,100,276.22 | Effect of the above items on
income tax | | Effect of minority equity (after tax) | 7,349,938.06 | The portion of the above
items to which minority
shareholders are entitled | | Total | 15,973,709.09 | |
Explanations for classifying items of extraordinary gains and losses defined in the Explanatory Announcement No. 1 for Public Company Information Disclosures –Extraordinary Gains or Losses as items of recurring gains or losses.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof √Applicable □N/A
| Item | Change (%) | Explanation | | Net cash flow from
operating activities | -71.55 | Mainly due to the increase in procurement
expenditure of raw materials and a decrease of
cash collections of sales revenue during the
Reporting Period. |
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons Thereof
Unit: Yuan Currency: RMB
| Balance Sheet | 31 March 2023 | 31 December
2022 | Change in
proportion
（%） | Main Reason | | Financial liabilities
held for trading | 4,759,250.98 | 755,634.43 | 529.84 | Mainly due to changes in exchange
rates forward foreign exchange
contracts. | | Contract liabilities | 118,380,947.47 | 292,977,730.74 | -59.59 | Mainly because part of the contract
payments received in advance in the
Period which met the conditions for
revenue recognition were
recognized as revenues. | | Employee benefits
payable | 361,917,343.05 | 573,010,571.46 | -36.84 | Mainly due to the payment of the
year end performance bonus for the
previous year. | | Treasury shares | 717,135,581.08 | 347,176,561.29 | 106.56 | Mainly due to increase of
repurchase of shares during the
Reporting Period. | | Other
comprehensive
income | -42,580,905.41 | 4,704,473.53 | -1005.12 | Mainly due to changes in the fair
value of other equity instrument
investments. | | Statement of
Income | January to
March 2023 | January to
March 2022 | Change in
proportion
（%） | Main Reason | | Financial expenses | -15,861,425.43 | -30,519,305.67 | N/A | Mainly due to an increase of
financial expenses as a result of
exchange losses. | | Income from
investments | 39,625,949.95 | 29,176,808.52 | 35.81 | Mainly due to the receipt of bonus
payments during the Reporting
Period. | | Gains from changes
in fair values | -27,478,190.74 | -54,151,999.18 | N/A | Mainly due to fluctuations in the
market value of the securities
investments held. | | Losses of credit
impairment | -15,459,174.59 | 217,773.10 | -7198.75 | Mainly due to the receivables and
the increase in the expected credit
loss for the Reporting Period as
compared with the previous period. | | Assets impairment
loss | 1,837,691.27 | -5,309,013.21 | N/A | Mainly due to the provision for
price decline of inventories for the
Reporting Period decreased as
compared with the previous period. | | Non-operating
income | 876,580.36 | 2,321,933.96 | -62.25 | Mainly due to the decrease in
income from disposal of scrap items
for the Reporting Period as
compared to the previous period. | | Non-operating
expenses | 3,698,829.74 | 2,084,578.34 | 77.44 | Mainly due to the increase in
expenditure of charitable donation
for the Reporting Period as
compared with the previous period. | | Cash Flow
Statement | January to
March 2023 | January to
March 2022 | Change in
proportion
（%） | Main Reason | | Net cash flow from
operating activities | 248,084,750.71 | 871,904,476.98 | -71.55 | Mainly due to the increase in
procurement expenditure of raw
materials and a decrease of cash
collections of sales revenue during
the Reporting Period. | | Net cash flow from
investing activities | -71,511,309.54 | -77,907,837.67 | N/A | Mainly due to the recovery of
investment amount and the
decreased investment of
construction of new plants for the
Reporting Period as compared with
the previous period. | | Net cash flow from
financing activities | -118,644,351.81 | 62,714,553.34 | -289.18 | Mainly due to the decrease in
repayment and borrowings received
for the Reporting Period as
compared with the previous period. | | Effect of foreign
exchange rate
changes on cash | -47,773,910.21 | -12,259,201.98 | N/A | Mainly due to changes in foreign
exchange rates resulting in an
increase in exchange loss from
foreign exchange funds held. | | Net increase in cash
and cash equivalents | 10,155,179.14 | 844,451,990.66 | -98.80 | Mainly due to the decrease in cash
generated from ordinary operating
activities and the increase in
procurement expenditure of raw
materials during the Reporting
Period. |
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary
shares as of the end of the Reporting
Period | 87,173 | Total number of holders of preferred
shares with restored voting rights as of
the end of the Reporting Period (if any) | 0 | | | | | Shareholdings of the top 10 shareholders | | | | | | | | Name of shareholder | Nature of
shareholder | Number of
shares held | Percentage
(%) | Number of
shares held
with selling
restrictions | Pledge, mark or lock-up | | | | | | | | Share
status | Number | | Shenzhen Baiyeyuan Investment Co.,
Ltd. (深圳市百业源投资有限公司) | Domestic non-
state-owned
legal person | 895,653,653 | 46.43 | 0 | Pledge | 95,679,725 | | Hong Kong Securities Clearing Company
Limited | Unknown | 110,920,501 | 5.75 | 0 | Unknown | | | Might Seasons Limited | Foreign legal
person | 51,931,021 | 2.69 | 0 | Unknown | | | Citibank, National Association | Unknown | 13,780,230 | 0.71 | 0 | Unknown | | | Huaxia Life Insurance Co., Ltd. - Own
fund | Unknown | 11,854,118 | 0.61 | 0 | Unknown | | | He Zhong | Domestic
natural person | 7,800,024 | 0.40 | 0 | Unknown | | | Agricultural Bank of China Limited - CSI
500 Exchange Traded Index Securities
Investment Fund | Unknown | 7,010,694 | 0.36 | 0 | Unknown | | | Joincare Pharmaceutical Group Industry
Co., Ltd. — the Second Phase Ownership
Scheme under Medium to Long-term
Business Partner Share Ownership
Scheme (健康元药业集团股份有限公司
－中长期事业合伙人持股计划之第二
期持股计划) | Others | 6,275,372 | 0.33 | 0 | - | | | Industrial Bank Co., Ltd. - Caitong Asset
Management Health Industry Hybrid
Securities Investment Fund | Unknown | 6,000,000 | 0.31 | 0 | Unknown | | | 108 protfolio of national social security
fund | Unknown | 5,857,721 | 0.30 | 0 | Unknown | | | Shareholdings of the top 10 shareholders without selling restrictions | | | | | | | | Name of shareholder | Number of tradable shares held
without selling restrictions | Class and number of shares | | | | | | | | Class of shares | Number | | | | | Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源
投资有限公司) | 895,653,653 | Ordinary shares
denominated in
Renminbi | 895,653,653 | | | | | Hong Kong Securities Clearing Company Limited | 110,920,501 | Ordinary shares
denominated in
Renminbi | 110,920,501 | | | | | Might Seasons Limited | 51,931,021 | Ordinary shares
denominated in
Renminbi | 51,931,021 | | | | | Citibank, National Association | 13,780,230 | Ordinary shares
denominated in
Renminbi | 13,780,230 | | | | | Huaxia Life Insurance Co., Ltd. - Own fund | 11,854,118 | Ordinary shares
denominated in
Renminbi | 11,854,118 | | | | | He Zhong | 7,800,024 | Ordinary shares
denominated in
Renminbi | 7,800,024 | | | | | Agricultural Bank of China Limited - CSI 500 Exchange
Traded Index Securities Investment Fund | 7,010,694 | Ordinary shares
denominated in
Renminbi | 7,010,694 | | | | | Joincare Pharmaceutical Group Industry Co., Ltd. — the
Second Phase Ownership Scheme under Medium to Long-
term Business Partner Share Ownership Scheme (健康元药
业集团股份有限公司－中长期事业合伙人持股计划之第
二期持股计划) | 6,275,372 | Ordinary shares
denominated in
Renminbi | 6,275,372 | | | | | Industrial Bank Co., Ltd. - Caitong Asset Management
Health Industry Hybrid Securities Investment Fund | 6,000,000 | Ordinary shares
denominated in
Renminbi | 6,000,000 | | | | | 108 protfolio of national social security fund | 5,857,721 | Ordinary shares
denominated in
Renminbi | 5,857,721 | | | |
| Description of connection or acting-in-concert relationship
of the above shareholders | There was no connection or acting-in-concert relationship between
Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the
Company, and other shareholders; whether there is connection or acting-in-
concert relationship among other shareholders is unknown. | | Description of the participation of the top 10 shareholders
and the top 10 shareholders without selling restrictions in
margin financing and securities lending and refinancing
business (if any) | As of the end of the Reporting Period, He Zhong, a shareholder, holds a total
of 7,800,024shares of the Company, including 800,000 shares held through
ordinary securities accounts and 7,000,024 shares held through credit
securities accounts. | | Description of the special repurchase account among the
top 10 shareholders | As of the end of the Reporting Period, the special repurchase account of the
Company (Special securities repurchase account of Joincare Pharmaceutical
Group Industry Co., Ltd.) owned 58,122,392 shares in total, accounting for
3.01%. |
Note: Citibank, National Association is the depositary of the Company’s GDRs (Global Depository Receipts),
the corresponding underlying domestic A Shares of GDRs shall be registered under its name according to the
laws; According to the depositary’s statistics, as of the end of the Reporting Period, the Company had a total of
1,378,023 GDRs outstanding accounting for 21.59% of the total number of GDRs issued by the Company.
III. OTHER REMINDERS
Other important information regarding the Company’s operations during the Reporting Period to which
investors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
31 March 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 31 March 2023 | 31 December 2022 | | Current assets: | | | | Monetary funds | 14,458,474,995.37 | 14,808,488,110.96 | | Financial assets held for trading | 85,646,883.17 | 109,015,664.98 | | Notes receivable | 2,202,720,144.84 | 1,959,985,016.85 | | Accounts receivable | 3,259,431,777.79 | 3,103,758,850.15 | | Receivables financing | | | | Prepayments | 457,539,057.82 | 364,265,142.57 | | Other receivables | 56,254,117.17 | 52,535,740.14 | | In which: Interests receivable | | | | Dividends receivable | | | | Inventories | 2,790,598,613.23 | 2,561,869,999.57 | | Contract assets | | | | Assets Held-for-sale | | | | Non-current assets due within one year | 54,581,111.11 | 54,048,611.11 | | Other current assets | 182,329,092.88 | 163,539,900.32 | | Total current assets | 23,547,575,793.38 | 23,177,507,036.65 | | Non-current assets: | | | | Debt investment | | | | Other debt investment | | | | Long-term receivables | | | | Long-term equity investment | 1,432,562,509.67 | 1,419,882,594.59 | | Other equity instrument investments | 1,149,287,217.20 | 1,193,958,879.05 | | Other non-current financial assets | | | | Investment properties | 6,191,475.43 | 6,191,475.43 | | Fixed assets | 5,230,295,232.48 | 5,265,200,110.91 | | Construction in progress | 909,461,674.66 | 811,300,068.96 | | Productive biological assets | | | | Oil and gas assets | | | | Right-of-use assets | 40,694,040.95 | 41,843,133.97 | | Intangible assets | 832,112,818.49 | 802,115,125.75 | | Development expenditures | 300,157,334.73 | 428,284,884.17 | | Goodwill | 636,339,503.82 | 614,468,698.73 | | Long-term deferred expenses | 290,036,796.09 | 277,867,716.95 | | Deferred income tax assets | 506,141,586.79 | 533,861,743.26 | | Other non-current assets | 1,312,195,031.38 | 1,156,772,182.99 | | Total non-current assets | 12,645,475,221.68 | 12,551,746,614.76 | | Total assets | 36,193,051,015.06 | 35,729,253,651.41 | | Current liabilities: | | | | Short-term loans | 2,099,069,713.00 | 2,126,050,615.06 | | Financial liabilities held for trading | 4,759,250.98 | 755,634.43 | | Notes payable | 1,659,215,210.65 | 1,635,906,989.22 | | Accounts payable | 1,044,610,610.21 | 943,905,580.91 | | Receipts in advance | | | | Contract liabilities | 118,380,947.47 | 292,977,730.74 | | Employee benefits payable | 361,917,343.05 | 573,010,571.46 | | Taxes payable | 302,213,706.06 | 337,702,273.73 | | Other payables | 3,650,990,302.39 | 3,680,334,360.88 | | In which: Interests payable | | | | Dividends payable | 11,892,804.66 | 12,252,074.84 | | Liabilities held-for-sale | | | | Non-current liabilities due within one year | 65,000,820.80 | 63,077,260.98 | | Other current liabilities | 88,863,541.97 | 101,276,714.35 | | Total current liabilities | 9,395,021,446.59 | 9,754,997,731.76 | | Non-current liabilities: | | | | Long-term loans | 3,666,476,993.70 | 3,230,844,042.88 | | Bonds payable | | | | Lease liabilities | 20,171,911.31 | 23,482,486.07 | | Long-term payables | | | | Long-term payroll payable | | | | Estimated liabilities | | | | Deferred income | 441,393,354.98 | 384,537,267.55 | | Deferred income tax liabilities | 232,294,155.75 | 231,164,425.48 | | Other non-current liabilities | 90,000,000.00 | 84,000,000.00 | | Total non-current liabilities | 4,450,336,415.73 | 3,954,028,221.98 | | Total liabilities | 13,845,357,862.33 | 13,709,025,953.74 | | Owner's equity (or shareholder's equity): | | | | Paid-in capital | 1,929,189,374.00 | 1,929,189,374.00 | | Other equity instruments | | | | In which: Preferred shares | | | | Perpetual debts | | | | Capital reserve | 2,541,441,353.22 | 2,343,693,215.99 | | Less: Treasury shares | 717,135,581.08 | 347,176,561.29 | | Other comprehensive income | -42,580,905.41 | 4,704,473.53 | | Special reserve | | | | Surplus reserve | 734,766,581.50 | 734,766,581.50 | | Undistributed profits | 8,919,389,509.85 | 8,456,643,326.82 | | Total owner's equity (or shareholder's equity)
attributable to the parent company | 13,365,070,332.08 | 13,121,820,410.55 | | Minority shareholder's equity | 8,982,622,820.65 | 8,898,407,287.12 | | Total owner's equity (or shareholder's equity) | 22,347,693,152.74 | 22,020,227,697.67 | | Total liabilities and owner's equity (or
shareholder's equity) | 36,193,051,015.06 | 35,729,253,651.41 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company's accounting work: accounting department: Qiu Qingfeng Qiu Qingfeng
Consolidated Income Statement
From January to March, 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First quarter (January to
March) for 2023 | First quarter (January to
March) for 2022 | | I. Total revenues | 4,559,049,786.82 | 4,657,343,538.89 | | In which: Operating revenues | 4,559,049,786.82 | 4,657,343,538.89 | | II. Total operating costs | 3,563,214,097.57 | 3,650,160,694.91 | | In which: Operating costs | 1,713,465,807.02 | 1,611,006,712.60 | | Operating tax and surcharges | 54,610,788.80 | 52,198,225.41 | | Selling expenses | 1,220,569,090.59 | 1,413,289,256.99 | | Administrative expenses | 209,257,340.10 | 252,854,561.35 | | R&D expenses | 381,172,496.49 | 351,331,244.23 | | Financial expenses | -15,861,425.43 | -30,519,305.67 | | In which: Interest expenses | 33,036,361.57 | 29,854,923.66 | | Interest income | 68,217,553.45 | 68,468,649.16 | | Add: Other income | 54,191,288.49 | 59,138,624.91 | | Income from investments (loss is
indicated by“-”) | 39,625,949.95 | 29,176,808.52 | | In which: Income from investments
in associates and joint ventures | 11,470,389.65 | 15,204,632.53 | | Gains from derecognition of
financial assets at amortized cost | | | | Gains from net exposure hedges
(loss is indicated by“-”) | | | | Gains from changes in fair values
(loss is indicated by“-”) | -27,478,190.74 | -54,151,999.18 | | Losses of credit impairment (loss is
indicated by“-”) | -15,459,174.59 | 217,773.10 | | Assets impairment loss (loss is
indicated by“-”) | 1,837,691.27 | -5,309,013.21 | | Gains from disposal of assets (loss
is indicated by“-”) | | -370,357.71 | | III. Operating profit (loss is indicated
by“-”) | 1,048,553,253.63 | 1,035,884,680.41 | | Add: Non-operating income | 876,580.36 | 2,321,933.96 | | Less: Non-operating expenses | 3,698,829.74 | 2,084,578.34 | | IV. Total profit (loss is indicated by“-”) | 1,045,731,004.25 | 1,036,122,036.03 | | Less: Income tax expenses | 167,212,968.94 | 173,764,775.30 | | V. Net profit (loss is indicated by“-”) | 878,518,035.31 | 862,357,260.73 | | (I) Classified by business continuity | | | | 1. Net profit from ongoing operation
(loss is indicated by“-”) | 878,518,035.31 | 862,357,260.73 | | 2. Net profit from discontinuing
operation (loss is indicated by“-”) | | | | (II) Classified by ownership | | | | 1.Net profit attributable to
shareholders of the parent company
(loss is indicated by“-”) | 462,746,183.03 | 460,537,813.53 | | 2.Profit and loss of minority
shareholders (loss is indicated by“-”) | 415,771,852.27 | 401,819,447.20 | | VI. Other comprehensive income, net of
tax | -83,671,573.75 | -106,847,774.60 | | (I) Other comprehensive income
attributable to owners of the parent
company, net of tax | -47,285,378.94 | -92,885,997.05 | | 1. Other comprehensive income that
cannot be reclassified into profit or
loss | -20,803,179.78 | -75,513,312.70 | | (1) Changes from remeasurement of
defined benefit plans | | | | (2) Other comprehensive income
that cannot be reclassified into profit or
loss under the equity method | | | | (3) Changes in fair value of
investments in other equity instruments | -20,803,179.78 | -75,513,312.70 | | (4) Changes in fair value of the
enterprise's own credit risks | | | | 2. Other comprehensive income that
will be reclassified into profit or loss | -26,482,199.17 | -17,372,684.35 | | (1) Other comprehensive income
that can be reclassified into profit or loss
under the equity method | | | | (2) Changes in fair value of other
debt investments | | | | (3) Amount of financial assets
reclassified into other comprehensive
income | | | | (4) Provision for credit impairment
of other debt investments | | | | (5) Reserve for cash flow hedges | | | | (6) Exchange translation differences
on financial statements denominated in
foreign currencies | -26,482,199.17 | -17,372,684.35 | | (7) Others | | | | (II) Other comprehensive income
attributable to minority shareholders,
net of tax | -36,386,194.81 | -13,961,777.55 | | VII. Total comprehensive income | 794,846,461.55 | 755,509,486.13 | | (I) Total comprehensive income
attributable to owners of the parent
company | 415,460,804.09 | 367,651,816.48 | | (II) Total comprehensive income
attributable to minority shareholders | 379,385,657.46 | 387,857,669.65 | | VIII. Earnings per share: | | | | (I) Basic earnings per share (RMB/share) | 0.2404 | 0.2411 | | (II) Diluted earnings per share
(RMB/share) | 0.2398 | 0.2410 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company's accounting work: accounting department: Qiu Qingfeng Qiu Qingfeng
Consolidated Cash Flow Statement
From January to March, 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First quarter
(January to
March) for 2023 | First quarter
(January to
March) for 2022 | | I. Cash flow from operating activities: | | | | Cash received from sales of goods and rendering of services | 4,361,096,155.32 | 4,614,758,574.74 | | Tax refunds received | 40,439,680.21 | 32,240,811.32 | | Other cash received related to operating activities | 202,829,024.01 | 172,771,264.97 | | Subtotal of cash inflow from operating activities | 4,604,364,859.54 | 4,819,770,651.03 | | Cash paid for goods and services | 1,563,463,357.75 | 1,165,780,579.10 | | Cash paid to and on behalf of employees | 820,337,183.05 | 758,821,581.15 | | Payments of all types of taxes | 541,191,286.96 | 420,627,138.84 | | Other cash paid related to operating activities | 1,431,288,281.07 | 1,602,636,874.96 | | Subtotal of cash outflow in operating activities | 4,356,280,108.83 | 3,947,866,174.05 | | Net cash flow from operating activities | 248,084,750.71 | 871,904,476.98 | | II. Cash flow from investing activities: | | | | Cash received from disposal of investment | 70,031,257.75 | 216,970,980.42 | | Cash received from investment income | 26,244,584.66 | 6,832,308.83 | | Net cash received from disposal of fixed assets, intangible
assets and other long-term assets | 88,664.00 | 346,152.00 | | Net cash received from disposal of subsidiaries and other
business units | | | | Other cash received related to investing activities | 297,605,105.05 | 7,668,394.07 | | Subtotal of cash inflow from investing activities | 393,969,611.46 | 231,817,835.32 | | Cash paid for purchase and construction of fixed assets,
intangible assets and other long-term assets | 244,675,030.69 | 277,850,093.60 | | Cash paid for investment | 6,183,753.84 | 30,338,557.45 | | Net cash paid for acquisition of subsidiaries and other
business units | 12,461,951.59 | | | Other cash paid related to investing activities | 202,160,184.88 | 1,537,021.94 | | Subtotal of cash outflow in investing activities | 465,480,921.00 | 309,725,672.99 | | Net cash flow from investing activities | -71,511,309.54 | -77,907,837.67 | | III. Cash flow from financing activities: | | | | Cash received from capital contribution | | 53,414,701.36 | | In which: Cash received from investment by minority
interests of subsidiaries | | | | Cash received from borrowings | 1,249,525,870.74 | 1,923,486,837.26 | | Other cash received related to financing activities | | 130,847,366.53 | | Subtotal of cash inflow from financing activities | 1,249,525,870.74 | 2,107,748,905.15 | | Cash repayments of amounts borrowed | 715,074,985.04 | 1,776,859,803.19 | | Cash payments for interest expenses and distribution of
dividends or profits | 41,156,153.68 | 19,177,786.10 | | In which: Dividends and profit paid minority interests of
subsidiaries | 359,270.18 | | | Other cash payments related to financing activities | 611,939,083.83 | 248,996,762.52 | | Subtotal of cash outflow in financing activities | 1,368,170,222.55 | 2,045,034,351.81 | | Net cash flow from financing activities | -118,644,351.81 | 62,714,553.34 | | IV. Effect of exchange rate fluctuations on cash and cash
equivalents | -47,773,910.21 | -12,259,201.98 | | V. Net increase in cash and cash equivalents | 10,155,179.14 | 844,451,990.66 | | Add: Opening balance of cash and cash equivalents | 14,178,465,686.40 | 11,697,518,141.18 | | VI. Closing balance of cash and cash equivalents | 14,188,620,865.54 | 12,541,970,131.84 |
（未完）
|
|
